Last reviewed · How we verify
ASP7374
ASP7374 is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases.
ASP7374 is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases. Used for Psoriasis, Inflammatory bowel disease.
At a glance
| Generic name | ASP7374 |
|---|---|
| Sponsor | UMN Pharma Inc. |
| Drug class | TYK2 inhibitor |
| Target | TYK2 (tyrosine kinase 2) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TYK2 is a non-receptor tyrosine kinase that plays a critical role in signal transduction downstream of type I and type III interferons and IL-12/IL-23 cytokines. By selectively inhibiting TYK2, ASP7374 reduces pathogenic Th17 and other pro-inflammatory immune responses. This mechanism is particularly relevant for autoimmune and inflammatory conditions where these cytokine pathways drive disease pathology.
Approved indications
- Psoriasis
- Inflammatory bowel disease
Common side effects
- Upper respiratory tract infection
- Headache
- Diarrhea
- Nasopharyngitis
Key clinical trials
- A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older (PHASE3)
- A Study to Evaluate Intramuscular ASP7374 (PHASE3)
- Study of ASP7374, Cell-culture-derived Influenza Vaccine (PHASE3)
- Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine (PHASE3)
- A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |